The LITESPARK-022 study tested belzutifan, an oral small-molecule inhibitor of hypoxia-inducible factor-2α (HIF-2α) targeting angiogenesis, in combination with standard of care pembrolizumab as ...

The trial enrolled 1,841 patients and measured DFS, with safety, OS, and quality of life as secondary endpoints.

Adding belzutifan to standard adjuvant pembrolizumab cut the risk for recurrence or death in patients with resected clear cell renal cell carcinoma.

The combination of belzutifan plus lenvatinib significantly improved outcomes for patients with clear cell renal cell carcinoma who progressed following immunotherapy compared with cabozantinib ...

Investigators are exploring whether combinational therapies can improve survival for patients with renal cell carcinoma or muscle-invasive bladder cancer.

Patients with a common form of kidney cancer called clear cell renal cell carcinoma (ccRCC) who have a high risk of ...

Belzutifan plus lenvatinib significantly improves outcomes vs single agent cabozantinib in patients with advanced RCC who progressed after anti-PD-(L)1 therapy, new data show.

The treatment landscape for clear cell renal cell carcinoma (ccRCC) could be due for a shake-up following dual breakthroughs ...

The 2026 GU ASCO annual meeting featured a renal cell carcinoma session and a discussant presentation by Dr. Beckermann, discussing three abstracts, “Belzutifan + lenvatinib versus cabozantinib for ...

We are continuing to see an increase in the incidence of kidney cancer in younger patients over time. Maintaining kidney health involves basic lifestyle choices: avoiding obesity, not smoking, and ...